UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7079-TPS7079

2023

Volltextzugriff (PDF)

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.7-8

2020

Volltextzugriff (PDF)

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

Anti-cancer drugs, 2001-03, Vol.12 (3), p.235-245

2001

Volltextzugriff (PDF)

A NOVEL IN VIVO HUMAN CYTOTOXIC T CELL

Pediatric research, 1987-04, Vol.21 (4), p.319-319A

1987

Volltextzugriff (PDF)

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

Retina (Philadelphia, Pa.), 2002-04, Vol.22 (2), p.143-152

2002

Volltextzugriff (PDF)

Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation

Journal of Virology, 1993-04, Vol.67 (4), p.2014-2025

1993

Volltextzugriff (PDF)

Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa

Journal of Virology, 1995-05, Vol.69 (5), p.3108-3116

1995

Volltextzugriff (PDF)

Recombinant Epstein-Barr Virus with Small RNA (EBER) Genes Deleted Transforms Lymphocytes and Replicates in vitro

Proceedings of the National Academy of Sciences - PNAS, 1991-02, Vol.88 (4), p.1546-1550

1991

Volltextzugriff (PDF)

Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan

Clinical cancer research, 2000-07, Vol.6 (7), p.2903-2912

2000

Volltextzugriff (PDF)

The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine

Molecular pharmacology, 2006-07, Vol.70 (1), p.303-310

2006

Volltextzugriff (PDF)

Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro

Journal of Virology, 1992-05, Vol.66 (5), p.2893-2903

1992

Volltextzugriff (PDF)

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL

Leukemia research, 2003-11, Vol.27 (11), p.1039-1050

2003

Volltextzugriff (PDF)

An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro

Journal of Virology, 1994-03, Vol.68 (3), p.1449-1458

1994

Volltextzugriff (PDF)

BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication

Journal of Virology, 1991-11, Vol.65 (11), p.5991-6000

1991

Volltextzugriff (PDF)

The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro

Journal of Virology, 1993-04, Vol.67 (4), p.2006-2013

1993

Volltextzugriff (PDF)

Epstein-Barr virus recombinants from overlapping cosmid fragments

Journal of Virology, 1993-12, Vol.67 (12), p.7298-7306

1993

Volltextzugriff (PDF)

Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B

Journal of Virology, 1993-08, Vol.67 (8), p.5068-5074

1993

Volltextzugriff (PDF)

Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors

Cancer chemotherapy and pharmacology, 2005-03, Vol.55 (3), p.213-221

2005

Volltextzugriff (PDF)

Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection

Journal of Virology, 1992-02, Vol.66 (2), p.780-789

1992

Volltextzugriff (PDF)

The Role of Human Nucleoside Transporters in Cellular Uptake of 4â²-Thio-Î²-d-arabinofuranosylcytosine and Î²-d-Arabinosylcytosine

Molecular pharmacology, 2006-07, Vol.70 (1), p.303

2006

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

A NOVEL IN VIVO HUMAN CYTOTOXIC T CELL

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation

Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa

Recombinant Epstein-Barr Virus with Small RNA (EBER) Genes Deleted Transforms Lymphocytes and Replicates in vitro

Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan

The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine

Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL

An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro

BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication

The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro

Epstein-Barr virus recombinants from overlapping cosmid fragments

Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B

Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors

Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection

The Role of Human Nucleoside Transporters in Cellular Uptake of 4â²-Thio-Î²-d-arabinofuranosylcytosine and Î²-d-Arabinosylcytosine

Suchergebnisse filtern